|Mr. John D. Young||Group Pres of Pfizer Innovative Health||4.42M||1.15M||1965|
|Mr. Ian C. Read||Chairman & CEO||6.38M||11.48M||1954|
|Mr. Frank A. D'Amelio||Exec. VP of Bus. Operations & CFO||3.24M||6.11M||1958|
|Mr. Albert Bourla D.V.M., DVM, Ph.D.||COO & Director||4.07M||587.28k||1962|
|Ms. Loretta V. Cangialosi||Sr. VP, Controller & Principal Accounting Officer||N/A||N/A||N/A|
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care. This segment offers products primarily under the Prevnar 13/Prevenar 13, Xeljanz, Eliquis, Lyrica, Enbrel, Ibrance, Xtandi, Advil, and Centrum brands. The EH segment offers products that would lose or have lost marketing patent protection; branded generic products; generic sterile injectable products; biosimilars; and anti-infectives. It provides products under the Lipitor, Premarin family, Norvasc, Lyrica, Celebrex, Viagra, Inflectra/Remsima, Pristiq, Zyvox, Vfend, Revatio, Inspra, Medrol, Sulperazon, Fragmin, Tygacil, Nivestim, and Retacrit brand names. This segment also engages in the research and development, as well as contract manufacturing activities. Pfizer Inc. has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company for the development of Eliquis; Astellas Pharma US, Inc. for developing Xtandi; Merck KGaA for the development of Bavencio; and Neofluidics, LLC to develop a microfluidics-based platform. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer Inc.’s ISS Governance QualityScore as of April 1, 2018 is 1. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 1; Compensation: 1.